Vanda Pharmaceuticals (VNDA) Common Equity (2010 - 2026)

Vanda Pharmaceuticals (VNDA) has 17 years of Common Equity data on file, last reported at $280.8 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 45.1% year-over-year to $280.8 million; the trailing twelve-month figure through Mar 2026 stood at $280.8 million (down 45.1% YoY), and the FY2025 full-year result was $327.2 million, down 39.25% from the prior year.
• Common Equity declined to $280.8 million in Q1 2026, from $327.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $544.9 million in Q4 2023 to a low of $280.8 million in Q1 2026.
• A 5-year average of $497.4 million and a median of $527.2 million in 2022 frame the typical range for Common Equity.
• Across the five-year window, Common Equity advanced 7.38% in 2022 and sank 45.1% in 2026, its largest moves.
• Tracing VNDA's Common Equity over 5 years: stood at $527.2 million in 2022, then increased by 3.36% to $544.9 million in 2023, then retreated by 1.17% to $538.5 million in 2024, then slumped by 39.25% to $327.2 million in 2025, then retreated by 14.19% to $280.8 million in 2026.
• Business Quant data shows VNDA's Common Equity at $280.8 million in Q1 2026, $327.2 million in Q4 2025, and $466.0 million in Q3 2025.